IBD: Exelixis (EXEL) Stock Breaks Out After Earnings Resistance, Up 0.08% Intraday to $59.08
IBD notes that Exelixis stock broke out past a 57.57 USD flat-base buy point, with the buy range extending up to 60.45 USD. The stock holds an IBD Composite Rating of 99/99 and an industry group rank of 27/197.
No AI analysis yet. Tap the "AI Analysis" button above to generate one now.
Disclaimer: This content reflects the author's personal views only and does not constitute investment advice.
24H Trending
-
1
U.S. Secretary of State Rubio visited India's Reliance refinery to discuss increasing the refining of Venezuelan crude oil, aiming to balance sanctions against Russia with oil price stability.
-
2
According to Al Jazeera, Israeli airstrikes targeted the outskirts of the southern Lebanese towns of Nabatieh al-Fawqa and Kfar Tebnit, with no immediate reports of damage.
-
3
ZachXBT: Over 87% of funds flowing into Hyperliquid's money laundering service FreedomXMR are linked to illicit activities, with over $20 million traceable to ransomware and other attacks.
-
4
CME Group announced that FalconX and GSR completed the first block trades of its newly launched Bitcoin Cash and Uniswap futures on October 20.
-
5
Iran Denies Imminent Economic Collapse, US Says Revolutionary Guard Faces Funding Shortages
-
6
Tx launches Brale-issued USTX stablecoin, mintable with USDC from eight networks, to pull RWA liquidity onto its chain for settling tokenized stocks and other assets.
-
7
Oracle, Meta, and SpaceX credit default swaps (CDS) hit all-time highs, as the market anticipates a surge in AI-related bond issuance in Q4.
-
8
SEC and Japan's FSA Held Autumn Financial Regulatory Dialogue in Tokyo on Oct. 19
-
9
Ontario International Airport plans to issue approximately $174 million in municipal bonds to finance several improvement projects.
-
10
UK Banks Face Scrutiny Over Crypto Transfer Limits Amid Thousands of Complaints
Markets Today
Recommended Reading


